Galderma announces CEO for North American Operations

Stuart Raetzman will join the dermatology firm on 1 March

Industry veteran Stuart Raetzman will join dermatology specialist Galderma as Chief Executive of Galderma Laboratories and Vice President North America on 1 March.

Raetzman joins the Swiss company after 20 years with Alcon, a division of Novartis, where he held senior leadership roles in the US and Europe. He has also worked for Allergan and Chiron Vision.

His career has been spent working across the spectrum of healthcare product categories including pharmaceuticals, biologics, disposable medical devices, implantable medical devices, capital equipment and over-the-counter products.

You may also like

Ingredients

Therapeutic: nemolizumab for prurigo nodularis

Prurigo nodularis is a debilitating chronic neuroimmunologic skin condition in which patients develop thick skin nodules covering large areas of the body
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Finance

Galderma acquires Spirig

Expanding its offering in dermatological products
Research & Development

AstraZeneca and Galderma to collaborate

Sign five-year deal to develop treatments for dermatological diseases
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Subscribe now